Applied DNA Sciences (NASDAQ:APDN) Now Covered by StockNews.com

Equities researchers at StockNews.com started coverage on shares of Applied DNA Sciences (NASDAQ:APDN) in a note issued to investors on Saturday. The firm set a “sell” rating on the technology company’s stock.

Separately, HC Wainwright reduced their target price on Applied DNA Sciences from $7.00 to $1.50 and set a “buy” rating on the stock in a report on Monday, June 10th.

Applied DNA Sciences Stock Down 0.7 %

Shares of NASDAQ:APDN opened at $0.41 on Friday. The company’s 50-day moving average price is $2.06 and its two-hundred day moving average price is $7.82. Applied DNA Sciences has a 12 month low of $0.37 and a 12 month high of $37.20. The firm has a market cap of $400,232.00, a P/E ratio of -0.02 and a beta of 0.08.

Applied DNA Sciences (NASDAQ:APDN) last issued its quarterly earnings results on Friday, May 10th. The technology company reported ($5.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($4.60) by ($0.71). The firm had revenue of $0.93 million for the quarter, compared to analyst estimates of $0.90 million. Applied DNA Sciences had a negative net margin of 222.33% and a negative return on equity of 306.32%. As a group, equities analysts predict that Applied DNA Sciences will post -2.95 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Applied DNA Sciences

A hedge fund recently bought a new stake in Applied DNA Sciences stock. Silverberg Bernstein Capital Management LLC purchased a new stake in Applied DNA Sciences, Inc. (NASDAQ:APDN) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 98,301 shares of the technology company’s stock, valued at approximately $61,000. Silverberg Bernstein Capital Management LLC owned about 0.72% of Applied DNA Sciences at the end of the most recent quarter. Hedge funds and other institutional investors own 22.22% of the company’s stock.

About Applied DNA Sciences

Applied DNA Sciences, Inc, a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services.